66P Incidence and impact on survival of venous thromboembolic events in patients with advanced non-small cell lung cancer receiving pembrolizumab as first-line of treatment

MLA

P. Hulo, et al. “66P Incidence and Impact on Survival of Venous Thromboembolic Events in Patients with Advanced Non-Small Cell Lung Cancer Receiving Pembrolizumab as First-Line of Treatment.” Annals of Oncology, vol. 33, Apr. 2022, p. S62. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.02.075.

APA

P. Hulo, H. Senellart, T. Chatellier, J. Bennouna, & E. Pons-Tostivint. (2022). 66P Incidence and impact on survival of venous thromboembolic events in patients with advanced non-small cell lung cancer receiving pembrolizumab as first-line of treatment. Annals of Oncology, 33, S62. https://doi.org/10.1016/j.annonc.2022.02.075

Chicago

P. Hulo, H. Senellart, T. Chatellier, J. Bennouna, and E. Pons-Tostivint. 2022. “66P Incidence and Impact on Survival of Venous Thromboembolic Events in Patients with Advanced Non-Small Cell Lung Cancer Receiving Pembrolizumab as First-Line of Treatment.” Annals of Oncology 33 (April): S62. doi:10.1016/j.annonc.2022.02.075.